R&D Tax Incentive Received
R&D Tax Incentive Received
Brisbane, Jan 18, 2018 AEST (ABN Newswire) - Anatara Lifesciences (ASX:ANR) is pleased to announce that it has received $1,230,329 from the Australian Taxation Office under the Federal Government's Research and Development (R&D) Tax Incentive scheme.

The refund is from Anatara's 2016-2017 research activities and reflects a period of significant investment into the Company's lead product, Detach(R), for the control of gastrointestinal disease in pigs, as well as activities designed to progress Anatara's human therapeutics pipeline.

Anatara's Chairman and CEO, Dr Mel Bridges said, "The 2016-2017 period was an important one for Anatara as we focused on moving Detach closer to market and prepared to expand our program into human applications. The R&D tax incentive provides an important source of non-dilutive funding and enables the Company to remain well funded as we progress our commercialisation activities."

About Anatara Lifesciences Ltd

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach(R) is a natural plant based product that aids in the control of diarrhoea and will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called "super bugs" that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.



Investor inquiries:
Dr Mel Bridges
Chairman & CEO, Anatara Lifesciences
Phone: +61-413-051-600
Email: mbridges@anatara.com

Media inquiries:
Jane Lowe
Managing Director, IR Department
Phone: +61-411-117-774
Email: jane.lowe@irdepartment.com.au

Related Companies

Anatara Lifesciences Ltd

ABN Newswire This Page Viewed:  (Last 7 Days: 44) (Last 30 Days: 200) (Since Published: 3204) 

Anatara Lifesciences Ltd NEWS: RECENT VISITS (3501)

Research Report

Social Media